Eli Lilly And Co (NYSE:LLY) declared a quarterly dividend on Monday, October 15th, RTT News reports. Shareholders of record on Thursday, November 15th will be given a dividend of 0.5625 per share on Monday, December 10th. This represents a $2.25 annualized dividend and a yield of 2.02%.
Eli Lilly And Co has raised its dividend by an average of 2.0% annually over the last three years and has raised its dividend annually for the last 3 consecutive years. Eli Lilly And Co has a payout ratio of 41.1% indicating that its dividend is sufficiently covered by earnings. Equities research analysts expect Eli Lilly And Co to earn $5.73 per share next year, which means the company should continue to be able to cover its $2.25 annual dividend with an expected future payout ratio of 39.3%.
LLY traded up $1.00 during midday trading on Monday, hitting $111.48. 143,963 shares of the company traded hands, compared to its average volume of 4,208,734. The company has a quick ratio of 1.09, a current ratio of 1.40 and a debt-to-equity ratio of 0.79. The company has a market cap of $115.25 billion, a price-to-earnings ratio of 25.78, a PEG ratio of 1.88 and a beta of 0.29. Eli Lilly And Co has a 52-week low of $73.69 and a 52-week high of $116.61.
Eli Lilly And Co (NYSE:LLY) last posted its quarterly earnings data on Tuesday, July 24th. The company reported $1.50 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.30 by $0.20. The business had revenue of $6.36 billion for the quarter, compared to the consensus estimate of $6.05 billion. Eli Lilly And Co had a negative net margin of 0.60% and a positive return on equity of 39.84%. The company’s revenue was up 9.1% compared to the same quarter last year. During the same period last year, the firm posted $1.11 earnings per share. On average, research analysts forecast that Eli Lilly And Co will post 5.47 EPS for the current year.
LLY has been the topic of several recent analyst reports. BMO Capital Markets increased their price objective on shares of Eli Lilly And Co from $78.00 to $80.00 and gave the company a “$89.43” rating in a report on Thursday, July 19th. TheStreet raised shares of Eli Lilly And Co from a “c+” rating to a “b” rating in a research note on Friday, June 29th. Cowen set a $105.00 price target on shares of Eli Lilly And Co and gave the stock a “buy” rating in a research note on Tuesday, July 24th. Cantor Fitzgerald set a $100.00 price target on shares of Eli Lilly And Co and gave the stock a “buy” rating in a research note on Tuesday, July 24th. Finally, Zacks Investment Research raised shares of Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $100.00 price target on the stock in a research note on Wednesday, July 18th. One research analyst has rated the stock with a sell rating, six have given a hold rating and twelve have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $108.60.
In related news, insider Donald A. Zakrowski sold 600 shares of the firm’s stock in a transaction dated Tuesday, September 4th. The shares were sold at an average price of $105.57, for a total transaction of $63,342.00. Following the completion of the sale, the insider now directly owns 3,530 shares in the company, valued at $372,662.10. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, major shareholder Lilly Endowment Inc sold 14,632 shares of the firm’s stock in a transaction dated Monday, October 8th. The stock was sold at an average price of $115.91, for a total transaction of $1,695,995.12. Following the sale, the insider now owns 119,191,172 shares of the company’s stock, valued at $13,815,448,746.52. The disclosure for this sale can be found here. Over the last three months, insiders sold 1,785,575 shares of company stock worth $180,166,130. Insiders own 0.11% of the company’s stock.
Eli Lilly And Co Company Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Read More: Analyzing a company’s cash flow statement
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.